Robert W. Duggan Acquires 56,054 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan bought 56,054 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the transaction, the director now owns 42,228,057 shares in the company, valued at $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Pulse Biosciences Trading Up 3.0 %

Shares of Pulse Biosciences stock opened at $17.65 on Friday. The firm has a 50-day simple moving average of $17.68 and a two-hundred day simple moving average of $16.42. Pulse Biosciences, Inc. has a fifty-two week low of $6.59 and a fifty-two week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the previous year, the business earned ($0.19) EPS.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a report on Thursday.

Institutional Investors Weigh In On Pulse Biosciences

Several large investors have recently bought and sold shares of PLSE. Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences in the first quarter valued at approximately $88,000. Quest Partners LLC purchased a new position in Pulse Biosciences in the 2nd quarter valued at $91,000. Cetera Advisors LLC acquired a new stake in Pulse Biosciences during the 1st quarter worth $109,000. Rhumbline Advisers boosted its stake in Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after purchasing an additional 1,608 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new stake in shares of Pulse Biosciences during the third quarter worth $378,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.